New Results from Post Hoc Analysis of APOLLO-B Phase 3 Study of Patisiran Presented during ESC 2023

26 Aug, 2023 New Results from Post Hoc Analysis of APOLLO-B Phase 3 Study of Patisiran Presented during ESC 2023

New results from a post hoc analysis of the APOLLO-B Phase 3 study of patisiran in patients with ATTR amyloidosis with cardiomyopathy evaluating disease progression following 12 months of treatment with patisiran vs. placebo were presented during the European Society of Cardiology (ESC) Congress 2023.

Damy, et al. “Evaluation of Disease Progression in Patients with ATTR Amyloidosis with Cardiomyopathy Following Treatment with Patisiran: Post hoc Analysis of the APOLLO-B Study”